Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc. ("Mimetogen") today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles. Mimetogen is in the process of completing its analysis of the data, and intends to present further details at a future medical conference.

"These preliminary results are very promising for the use of MIM-D3 for the treatment of dry eye disease," said Garth Cumberlidge, President and CEO of Mimetogen. "MIM-D3, a novel growth factor mimetic, represents a potential first-in-class therapy for the estimated $1 billion US market."

"We are very excited by the impressive results that Mimetogen has demonstrated in this Phase II trial, and we look forward to advising them on their strategic options going forward," said Kevin Giese, President and CEO of Medwell Capital Corp.